AIM ImmunoTech is trading at $0.24 (5.6% down) as investors continue to react to shareholder approval of a reverse stock split and significant dilutive share issuance capacity following the July 15 special meeting.
- The company gained authority to implement a reverse stock split of up to 1-for-25 at the board’s discretion.
- Shareholders approved the potential issuance of over 19.99% new common stock tied to warrants and promissory notes, raising significant concerns regarding capital structure and ongoing dilution.